Pharmaceutical Politics
How the global pharmaceutical industry shapes health outcomes through pricing, patents, and political influence, and the ongoing battle over access to medicines.
Patents, Profits, and Access
The global pharmaceutical industry generates over $1.4 trillion in annual revenue. Patent protection, which grants exclusive rights to produce and sell a drug for 20 years, is the industry's foundational business model. Companies argue that patents incentivize the enormous investment needed to develop new drugs: bringing a new drug to market costs an average of $1-2 billion when accounting for failed candidates. Without patent protection, they argue, innovation would collapse.
But patents create a fundamental tension with access to medicines. When a company holds a monopoly on a life-saving drug, it can set prices that exclude most of the world's population. Gilead's hepatitis C cure Sovaldi launched at $84,000 for a 12-week course in the US, while the generic version costs under $100 in India. This pricing gap means that millions of people in developing countries cannot access medicines that exist and work, a situation that many consider a moral catastrophe.
